India, March 4 -- Shares of Capricor Therapeutics, Inc. (CAPR) surged 12% on Tuesday morning after the biotechnology company announced the U.S. FDA's acceptance and priority review of its Biologics License Application for Deramiocel to treat Duchenne muscular dystrophy.
CAPR is currently trading at $15.39, up $1.72 or 12.58%, on the Nasdaq. The stock opened its trading at $15.11 after closing Monday at $13.67. The stock has traded between $3.52 and $23.40 in the past 52-week period.
Capricor Therapeutics announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne musc...